Retatrutide Phase 3 Data Is In — Now Comes the Hard Part
Retatrutide Phase 3 has delivered its first pivotal result, and the efficacy numbers are not in doubt. What happens next — manufacturing at scale and persuading payers to cover it — will determine whether those numbers translate into actual patient access, or whether Lilly repeats the Mounjaro supply bottleneck at a higher order of complexity. … Read more